Difference between revisions of "Team:SDU CHINA"

Line 29: Line 29:
 
<div class="highlight">
 
<div class="highlight">
 
<h5> Project Abstract </h5>
 
<h5> Project Abstract </h5>
−
<p>The incidence of cancer is increasing in modern society. In all cancer patients, P53 mutations account for nearly 50%. If the mutant P53 can be replaced with wild P53 using gene therapy method, it will be the best theropy for those patients. In our project, we are using CRISPR technique to cut the mutant p53 in tumor cells. In the process of genome repair, wild p53 will be integrated into genome via the principle of homologous recombination, restructuring the genome of cancer cells so as to realize the replacement of mutant p53. The characteristics of our project is that after the mutant p53 is replaced, the transfected plasmids will commit suicide. Even if the plasmids are transfected into the nontumorous cells, plasmids will also cut and degrade themselves. So it will not pose a threat to normal cells, achieving the safety of gene therapy.</p>  
+
<p>Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death among the world with low overall survival rate. In NSCLC, immunotherapy has been indicated as a potential therapy for treating in situ solid tumor. Previous research has indicated that tumor cells can express programmed death-1 ligand (PD-L1) to diminish T-cell effector functions and therefore to achieve immune escape. In our project, gene edition will be incorporated with immunotherapy to eradicate the immune escape occurred in NSCLC. By constructing plasmid with Crispr-Cas 9 system targeting the gene coding for PD-L1, the expression of PD-L1 will be inhibited to restore immune system supervision. To ensure the biosafety, another plasmid with Crsipr-Cas 9 system to cut off the housekeeping gene of two plasmids will be also constructed to suicide both plasmid when PD-L1 expression was not detectable. Better therapeutic effects of immunotherapy to conquer the NSCLC are hoped to be achieved.
 +
</p>  
 
</div>
 
</div>
 
</div>
 
</div>

Revision as of 00:08, 2 September 2017

Welcome to iGEM 2017!

Your team has been approved and you are ready to start the iGEM season!

Before you start:

Please read the following pages:

Project Abstract

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death among the world with low overall survival rate. In NSCLC, immunotherapy has been indicated as a potential therapy for treating in situ solid tumor. Previous research has indicated that tumor cells can express programmed death-1 ligand (PD-L1) to diminish T-cell effector functions and therefore to achieve immune escape. In our project, gene edition will be incorporated with immunotherapy to eradicate the immune escape occurred in NSCLC. By constructing plasmid with Crispr-Cas 9 system targeting the gene coding for PD-L1, the expression of PD-L1 will be inhibited to restore immune system supervision. To ensure the biosafety, another plasmid with Crsipr-Cas 9 system to cut off the housekeeping gene of two plasmids will be also constructed to suicide both plasmid when PD-L1 expression was not detectable. Better therapeutic effects of immunotherapy to conquer the NSCLC are hoped to be achieved.

Wiki template information

We have created these wiki template pages to help you get started and to help you think about how your team will be evaluated. You can find a list of all the pages tied to awards here at the Pages for awards link. You must edit these pages to be evaluated for medals and awards, but ultimately the design, layout, style and all other elements of your team wiki is up to you!

Editing your wiki

On this page you can document your project, introduce your team members, document your progress and share your iGEM experience with the rest of the world!

Use WikiTools - Edit in the black menu bar to edit this page

Tips

This wiki will be your team’s first interaction with the rest of the world, so here are a few tips to help you get started:

  • State your accomplishments! Tell people what you have achieved from the start.
  • Be clear about what you are doing and how you plan to do this.
  • You have a global audience! Consider the different backgrounds that your users come from.
  • Make sure information is easy to find; nothing should be more than 3 clicks away.
  • Avoid using very small fonts and low contrast colors; information should be easy to read.
  • Start documenting your project as early as possible; don’t leave anything to the last minute before the Wiki Freeze. For a complete list of deadlines visit the iGEM 2017 calendar
  • Have lots of fun!
Inspiration

You can also view other team wikis for inspiration! Here are some examples:

Uploading pictures and files

You can upload your pictures and files to the iGEM 2017 server. Remember to keep all your pictures and files within your team's namespace or at least include your team's name in the file name.
When you upload, set the "Destination Filename" to
T--YourOfficialTeamName--NameOfFile.jpg. (If you don't do this, someone else might upload a different file with the same "Destination Filename", and your file would be erased!)

UPLOAD FILES